Compare IGC & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IGC | HBIO |
|---|---|---|
| Founded | 2005 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 33.8M |
| IPO Year | N/A | 2000 |
| Metric | IGC | HBIO |
|---|---|---|
| Price | $0.35 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.13 | $2.50 |
| AVG Volume (30 Days) | 496.5K | ★ 1.0M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,106,000.00 | ★ $87,371,000.00 |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $15.12 | $7.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.28 |
| 52 Week High | $0.50 | $2.36 |
| Indicator | IGC | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 58.94 |
| Support Level | $0.28 | $0.71 |
| Resistance Level | $0.36 | $0.81 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 86.10 | 57.37 |
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.